Product Launch Announcement: Abiramale 500 (Abiraterone Acetate 500mg) Tablet
We are proud to introduce Abiramale 500 is an oral hormonal anti-cancer therapy containing Abiraterone Acetate 500mg, indicated for the management of advanced prostate cancer. By effectively suppressing androgen production, Abiramale 500 helps slow disease progression and supports improved survival outcomes in patients with metastatic disease.
🔍 Product Overview
Generic Name: Abiraterone Acetate 500mg
Strength: 500mg
Formulation: Tablet
Primary Indications:
Abiramale 500 (Abiraterone Acetate 500mg) is indicated for:
- Metastatic castration-resistant prostate cancer (mCRPC)
- Metastatic hormone-sensitive prostate cancer (mHSPC)
- Used in combination with prednisone or prednisolone
Mechanism of Action:
Abiraterone Acetate selectively inhibits CYP17 (17α-hydroxylase/C17,20-lyase), a critical enzyme involved in androgen biosynthesis. This results in reduced androgen production in the testes, adrenal glands, and tumor tissue, thereby limiting prostate cancer growth.
💡 Key Benefits
- Effective suppression of androgen synthesis
- Proven efficacy in advanced prostate cancer
- Oral therapy for convenient administration
- Improves progression-free and overall survival
- Well-established safety profile under medical supervision
🎯 Target Audience
- Medical oncologists
- Urologists
- Cancer treatment centers and hospitals
- Specialty oncology pharmacies
🏥 Commitment to Clinical Excellence
Abiramale 500 (Abiraterone Acetate 500mg) is manufactured in compliance with Good Manufacturing Practices (GMP) and stringent quality standards. Each tablet undergoes rigorous quality control to ensure consistent potency, safety, and therapeutic reliability for prostate cancer care.
📦 Availability
Abiramale 500 (Abiraterone Acetate 500 mg) Tablets are available through authorized distributors and healthcare supply channels. For supply inquiries, bulk orders, or regulatory documentation, please contact our sales or distribution team.
Abiramale 500– Focused Treatment for a Stronger Tomorrow
